The University of Alabama at Birmingham (UAB) received a $208,271 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The grant supports research to determine the in vivo role of the epigenetic regulator EZH2 in conferring resistance to the bispecific T-cell engager antibody tarlatamab in small cell lung cancer (SCLC) and evaluate pharmacological inhibition of EZH2 to enhance tarlatamab's efficacy. The key objectives are to model the impact of genetic and pharmacological inhibition of EZH2 on tarlatamab resistance in SCLC using mouse models, and elucidate the canonical and non-canonical functions of EZH2 in driving tarlatamab resistance. This research aims to identify a novel therapeutic approach to improve the efficacy of tarlatamab, an emerging targeted therapy for SCLC. The grant period runs from April 1, 2025 to March 31, 2027.
Generated 2/25/25, 1:46 AM